Clinical studies with anticoagulants to improve survival in cancer patients

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 3-4, 2008, Pages 204-211

  Gerotziafas, Grigoris T ^a,b,e   Papageorgiou, Chryssoula ^c   Hatmi, Mohamed ^d   Samama, Meyer Michel ^d   Elalamy, Ismail ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d HÔTEL DIEU   (France)

^e HÔPITAL TENON   (France)

Author keywords

Antithrombotic drugs; Low molecular weight heparins; Small cell lung cancer; Tumor growth and metastasis; Unfractionated heparin; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; CERTOPARIN; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ANGIOGENESIS; ANTICOAGULANT THERAPY; BLOOD CLOTTING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; CYTOLOGY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; LIFE EXPECTANCY; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOSIS; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; VENOUS THROMBOEMBOLISM; ANIMAL; BLEEDING; BLOOD; CHEMICALLY INDUCED DISORDER; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG SCREENING; META ANALYSIS; METASTASIS; METHODOLOGY; MORTALITY; MOUSE; MULTICENTER STUDY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SURVIVAL; THROMBOPHILIA;

ANIMALS; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG SCREENING ASSAYS, ANTITUMOR; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; META-ANALYSIS AS TOPIC; MICE; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL ANALYSIS; THROMBOPHILIA; THROMBOSIS; VITAMIN K; WARFARIN;

EID: 61449105940     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000175158     Document Type: Review

References (46)

1. Trousseau A: Phlegmasia alba dolens;in Trousseau A (ed): Clinique médicinale de l'Hôtel-Dieu de Paris. Paris, J.-B. Baillière &Fils, 1865, pp 645-712.
2. Bouillaud M: De l'oblitération des veines et de son influence sur la formation des hydropisies partielles. Arch Gen Med 1823;1:188-204.
3. Illtyd James TG, Matheson NM: Thrombophlebitis in cancer. Practitioner 1935;134: 683-684.
4. Zwicker JI, Furie BC, Furie B: Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007;62:126-136.
5. Goerner A: The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1931;16:369-372.
6. Hilgard P, Thomas RD: Perspectives in cancer research. Anticoagulants in the therapy of cancer. Am J Cancer 1976;12:755-762.
7. Kummer D, Kraml F: Studies on thymidine triphosphate synthesis in malignant tumors. II. Effect of hyperthermia, vitamin K and cytoxic agents (in German). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977;88:145-156.
8. Egilsson V: Cancer and vitamin K. Lancet 1977;ii:254-255.
9. Poggi S, Mussoni L, Kornblihtt L, Ballabio E, de Gaetano G, Donati MB: Warfarin enan-tiomers, anticoagulation and experimental tumour metastasis. Lancet 1978;i:163-164.
10. Bell RG: Vitamin K and chemical carcinogenesis. Lancet 1978;i:1161.
11. DiPalma JR, McMichael R: The interaction of vitamins with cancer chemotherapy. CA Cancer J Clin 1979;29:280-286.
12. Folkman J, Langer R, Linhardt RJ, et al: An-giogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221: 719-725.
13. Folkman J, Shing Y: Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-364.
14. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R: The ability of different forms of heparin to suppress P-selectin function in vitro correlates to their inhibitor y c apacit y on blood-borne met a stasis in vivo. Thromb Haemost 2006;95:535-540.
15. Borsig L: Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb He-most 2007;33:540-546.
16. Mousa SA: Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002;28:45-52.
17. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC: Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 1981;245:831-835.
18. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF, et al: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53: 2046-2052.
19. Maurer LH, Herndon IJ, Hollis DR, Aisner J, Carey RW, Skarin AT, et al: Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15: 3378-3387.
20. Chahinian AP, Propert KJ, Ware JH, Zim-mer B, Perry MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis RL et al: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002.
21. Daly L: The first international urokinase/ warfarin trial in colorectal cancer. Clin Exp Metastasis 1991;9:3-11.
22. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D et al: Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889.
23. Smorenburg SM, Vink R, Otten HM, et al: The effects of vitamin K antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 2001;86: 1586-1587.
24. Akl EA, Kamath G, Kim SY, Yosuico V, Bar-ba M, Terrenato I, Sperati F, Schünemann HJ: Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev 2007;2:CD006466.
25. Prandoni P, Lensing AWA, Piccioli A, Ber-nardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
26. Kakkar AK, Hedges AR, Williamson RCN, et al: Preoperative heparin therapy inhibits late deaths from metastatic cancer. Int J Oncol 1995;6:885-888.
27. Von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RF, Lersch C: Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98:434-439.
28. Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F, Büyükcelik A: Low-molecular-weight heparin increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic ca ncer. J Surg Oncol 2007;95:507-512.
29. Lee AY, Levine MN, Baker RI Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Math M, Haley S, Kovacs MJ, Gent M: Low-molecular-weight heparin versus a couma-rin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
30. Lee AYY, Julian A, Levine MN et al: Impact of dalteparin low-molecular-weight heparin on survival: results of a randomized trial in cancer patients with venous thromboembo-lism. Proc Am Soc Clin Oncol 20 03;22:211.
31. Thodiyil P, Kakkar AK: Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev 2002;28:151-155.
32. Falanga A, Piccioli A: Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med 2005;11:403-407.
33. Zacharski LR, Prandoni P, Monreal E: Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005;10:72-79.
34. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E: Subcutaneous heparin treatment increases survival in small cell lung cancer. 'Petites Cellules' Group. Cancer 1994;74:38-45.
35. Von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L: Effect of low-molecular-weight heparin (cer-toparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000;16:815-824.
36. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.
37. Kakkar AK, Levine MN, Kadziola Z, Le-moine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN: Low-molecular-weight heparin, therapy with dalteparin, and survival in advanced cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
38. Klerk CPW, Smorenburg SM, Otten HM, Lensing AWA, Prins MH, Piovella F, Prandoni P, Bos MMEM, Richel DJ, van Tienhoven G, Buller HR: The effect of low-molecular-weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
39. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL: Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81:758-767.
40. Robins HI, O'Neill A, Gilbert M, Olsen M, Sapiente R, Berkey B, Mehta M: Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008;62:227-233.
41. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR: The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev 2007;33:358-368.
42. Kuderer NM, Khorana AA, Lyman GH, Francis CW: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. Impact on survival and bleeding complications. Cancer 2007;110:1149-1160.
43. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA: The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5:729-737.
44. Akl EA, van Doormaal FF, Barba M, Kamath G, Kim YS, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Schünemann HJ: Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.
45. Akl EA, Muti P, Schünemann HJ: Anticoagulation in patients with cancer: an overview of reviews. Pol Arch Med Wewn 2008;118: 183-193.
46. Lyman GH, Khorana AA, Falanga AA, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CD: American Society of Clinical Oncology Guideline: recommendations for venous thromboem-bolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25: 5 4 9 0- 5505.